Image
Achieving Balance Practical Management Strategies for Opioid-Induced Constipation

Jeffrey Gudin, MD; Anthony J. Lembo, MD

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca.

Faculty

Jeffrey A. Gudin, MD
Director, Pain Management and Palliative Care
Englewood Hospital and Medical Center
Englewood, New Jersey
Clinical Instructor, Anesthesiology
Icahn School of Medicine at Mount Sinai
New York, New York

Anthony J. Lembo, MD
Associate Professor of Medicine
Director, GI Motility Laboratory
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Evaluate patients on chronic opioid therapy for bowel function and risk factors for OIC development
  • Compare the mechanisms of action and clinical profiles of current prescription medications for OIC
  • Construct evidence-based treatment regimens for patients with OIC that reflect bowel symptoms, prior treatment response, and patient preferences

Target Audience

The Interactive Professor™ is intended to help primary care providers (PCPs), including physicians, physician assistants, nurse practitioners, and other allied healthcare professionals anticipate, assess, and comprehensively manage constipation in patients who are being treated with prescription opioids.

Statement of Need/Program Overview

Although constipation commonly occurs with chronic opioid therapy, it often goes unrecognized by clinicians, exposing patients to potential medical complications and poor quality of life. During this Interactive Professor™ program, expert faculty will share time-sensitive strategies for assessing bowel patterns as well as prophylactic and more intensive bowel regimens. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

Instructions to Receive Credit

In order to receive credit for this activity, the participant must pass the posttest with a score of at least 70% and complete the application for credit.

System Requirements

PC/MAC: Supports any web browser.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jeffrey Gudin, MD    Speakers Bureau: AstraZeneca plc, Daiichi Sankyo Company, Limited, and Salix Pharmaceuticals, Inc. Consultant: AstraZeneca plc, Daiichi Sankyo Company, Limited, and Salix Pharmaceuticals, Inc.

Anthony J. Lembo, MD    Consultant: AstraZeneca plc; Ironwood Pharmaceuticals, Inc. Salix Pharmaceuticals, Inc., and Valeant Pharmaceuticals International, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Amanda Glazar, PhD      Nothing to disclose
Andrea Funk      Nothing to disclose
Laura Gilsdorf      Nothing to disclose
Jim Kappler, PhD      Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 03/13/2017

type Webcast